智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2025年6月2日，本公司董事会获本公司其中一名控股股东Rubymab Ltd.(卖方)告知，其已与Morgan Stanley & Co. International plc(独家配售代理)订立股份配售协议，独家配售代理已同意作为卖方的代理，促使买方购买Rubymab Ltd.持有的合共 1460万股本公司现有股份(股份)(于本公告日期占本公司已发行股本总数(包括库存股份)的约1.51%)，价格为每股股份8.05港元，如未能成功，则由独家配售代理自行购买(配售事项)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.